Eliana Merle
Stock Analyst at UBS
(2.95)
# 1,456
Out of 4,979 analysts
97
Total ratings
42.25%
Success rate
1.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eliana Merle
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GOSS Gossamer Bio | Upgrades: Buy | $1.25 → $9 | $2.77 | +224.91% | 3 | Sep 10, 2025 | |
| ALT Altimmune | Maintains: Buy | $26 → $24 | $3.78 | +534.92% | 2 | Aug 13, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Neutral | $8 → $9 | $13.60 | -33.82% | 4 | Aug 12, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $458 → $523 | $447.79 | +16.80% | 5 | Aug 12, 2025 | |
| ANAB AnaptysBio | Maintains: Neutral | $18 → $20 | $22.13 | -9.62% | 5 | Aug 12, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $306 → $307 | $202.91 | +51.30% | 2 | Aug 8, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $113 → $114 | $55.69 | +104.70% | 3 | Aug 5, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $403 → $550 | $482.13 | +14.08% | 3 | Aug 1, 2025 | |
| SRPT Sarepta Therapeutics | Downgrades: Neutral | $45 → $12 | $17.64 | -31.97% | 1 | Jul 21, 2025 | |
| PROK ProKidney | Maintains: Buy | $4 → $8 | $2.21 | +261.99% | 1 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $5.5 | $5.38 | +2.23% | 3 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $74 → $21 | $8.00 | +162.50% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $70 | $43.48 | +60.99% | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $70 | $24.47 | +186.06% | 7 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $72 | $53.50 | +34.58% | 3 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $44 | $26.84 | +63.93% | 8 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $38 | $8.63 | +340.32% | 3 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $109 | $44.62 | +144.29% | 4 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $2.2 | $1.60 | +37.50% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $71 | $40.94 | +73.42% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $11.82 | +136.89% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $6.89 | +74.17% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $3 | $5.36 | -44.03% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $97 → $131 | $102.09 | +28.32% | 6 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $5 | $10.06 | -50.30% | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $18 | $7.55 | +138.41% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $42 | $17.49 | +140.14% | 4 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $4.83 | +355.49% | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $9.86 | +376.92% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $7.89 | +102.79% | 2 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $192 → $134 | $32.77 | +308.91% | 3 | Aug 19, 2020 |
Gossamer Bio
Sep 10, 2025
Upgrades: Buy
Price Target: $1.25 → $9
Current: $2.77
Upside: +224.91%
Altimmune
Aug 13, 2025
Maintains: Buy
Price Target: $26 → $24
Current: $3.78
Upside: +534.92%
RAPT Therapeutics
Aug 12, 2025
Maintains: Neutral
Price Target: $8 → $9
Current: $13.60
Upside: -33.82%
Madrigal Pharmaceuticals
Aug 12, 2025
Maintains: Buy
Price Target: $458 → $523
Current: $447.79
Upside: +16.80%
AnaptysBio
Aug 12, 2025
Maintains: Neutral
Price Target: $18 → $20
Current: $22.13
Upside: -9.62%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $306 → $307
Current: $202.91
Upside: +51.30%
BioMarin Pharmaceutical
Aug 5, 2025
Maintains: Buy
Price Target: $113 → $114
Current: $55.69
Upside: +104.70%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Buy
Price Target: $403 → $550
Current: $482.13
Upside: +14.08%
Sarepta Therapeutics
Jul 21, 2025
Downgrades: Neutral
Price Target: $45 → $12
Current: $17.64
Upside: -31.97%
ProKidney
Jul 15, 2025
Maintains: Buy
Price Target: $4 → $8
Current: $2.21
Upside: +261.99%
Jun 26, 2025
Downgrades: Neutral
Price Target: $12 → $5.5
Current: $5.38
Upside: +2.23%
May 15, 2025
Maintains: Buy
Price Target: $74 → $21
Current: $8.00
Upside: +162.50%
May 13, 2025
Maintains: Buy
Price Target: $72 → $70
Current: $43.48
Upside: +60.99%
May 2, 2025
Maintains: Buy
Price Target: $78 → $70
Current: $24.47
Upside: +186.06%
Apr 30, 2025
Maintains: Buy
Price Target: $65 → $72
Current: $53.50
Upside: +34.58%
Apr 29, 2025
Initiates: Overweight
Price Target: $44
Current: $26.84
Upside: +63.93%
Jan 31, 2025
Maintains: Buy
Price Target: $25 → $38
Current: $8.63
Upside: +340.32%
Jan 31, 2025
Maintains: Buy
Price Target: $42 → $109
Current: $44.62
Upside: +144.29%
Jan 28, 2025
Maintains: Neutral
Price Target: $5 → $2.2
Current: $1.60
Upside: +37.50%
Jan 8, 2025
Maintains: Buy
Price Target: $65 → $71
Current: $40.94
Upside: +73.42%
Jan 7, 2025
Initiates: Buy
Price Target: $28
Current: $11.82
Upside: +136.89%
Nov 12, 2024
Initiates: Buy
Price Target: $12
Current: $6.89
Upside: +74.17%
Nov 12, 2024
Initiates: Neutral
Price Target: $3
Current: $5.36
Upside: -44.03%
Sep 18, 2024
Maintains: Neutral
Price Target: $97 → $131
Current: $102.09
Upside: +28.32%
Apr 4, 2024
Maintains: Neutral
Price Target: $3 → $5
Current: $10.06
Upside: -50.30%
Mar 27, 2024
Maintains: Buy
Price Target: $19 → $18
Current: $7.55
Upside: +138.41%
May 19, 2023
Maintains: Buy
Price Target: $45 → $42
Current: $17.49
Upside: +140.14%
Oct 13, 2022
Initiates: Buy
Price Target: $22
Current: $4.83
Upside: +355.49%
Jun 23, 2022
Maintains: Buy
Price Target: $51 → $47
Current: $9.86
Upside: +376.92%
May 21, 2021
Initiates: Buy
Price Target: $16
Current: $7.89
Upside: +102.79%
Aug 19, 2020
Maintains: Neutral
Price Target: $192 → $134
Current: $32.77
Upside: +308.91%